To evaluate the safety and tolerability of benralizumab
open-label, single treatment arm, multicentre, basket study to evaluate safety, PK, PD, efficacy, and immunogenicity of repeat dosing of benralizumab
Age 6 to <18 years of age, greater than or equal to 15kg, with a documented EGPA diagnosis for > 6 months before screening visit with hsitory or presence of asthma and eosinophilia. Documentation of 2: Biopsy with histopathological evidence of eosinophilic disease, neuropathy, pulmonary infiltrates, sino-nasal abnormality, cardiomyopathy, glomerulonephritis, alveolar haemorrhage, palpable purpura, positive ANCA test for MPO or PR3.
Principal Investigator